Physician profile

Ann Cooper

Family Medicine · Norfolk, VA

NPI 1386617025

$238.53

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$212.24

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $55.83 2019-2024 Zepbound, Jardiance, Mounjaro
Novo Nordisk INC $48.97 2019-2024 Ozempic, Rybelsus, Wegovy
Astrazeneca Pharmaceuticals Lp $42.94 2023-2024 Farxiga, Breztri
Grifols USA, LLC $21.13 2023 Prolastin-C Liquid
Dexcom, INC. $20.33 2024 Dexcom G6 Transmitter
Pfizer INC. $19.70 2024
Paratek Pharmaceuticals, INC. $16.03 2024 Nuzyra
Glaxosmithkline, LLC. $13.60 2023 Trelegy Ellipta, Shingrix

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ann Cooper

$238.53

in general payments reported 2019-2025

Years
2019-2024
Top company
Lilly USA, LLC

https://glasscript.com/doctor/62178/ann-cooper

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.